R. Kotchie

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.

A. Palmer, G. Goodall, W. Valentine, 2008, Current medical research and opinion.

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom

E. Bateman, A. Briggs, Y. Samyshkin, 2013, The European Journal of Health Economics.

Indirect Comparison of Once Daily Insulin Detemir and Glargine in Reducing Weight Gain and Hypoglycaemic Episodes when Administered in Addition to Conventional Oral Anti-Diabetic Therapy in Patients with Type-2 Diabetes

W. Fakhoury, C. Lereun, M. Aagren, 2008, Pharmacology.

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies

P. Thuresson, C. Nicolay, U. Kiiskinen, 2015, ClinicoEconomics and outcomes research : CEOR.

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis

Y. Samyshkin, S. Humphreys, N. Hertel, 2012, International journal of chronic obstructive pulmonary disease.

Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China

W. Valentine, S. Nielsen, J. Palmer, 2008, Advances in therapy.

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study

A. Palmer, G. Goodall, W. Valentine, 2008 .